Search results
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
This edition marks the start of the charity's 50th anniversary year. It includes lots of ways to get involved over the next 12 months along with details of our Annual and Professionals' Conferences in September.
Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Do you know your facts from your fiction? Host a quiz for Retina UK and raise vital funds for our ground-breaking work.
Skydiving is an exhilarating experience, and you can do this while supporting our cause. Various dates and locations are available across the UK.
As people living with sight loss we are constantly looking for solutions to make our lives easier without too much effort or cost writes Jonathan Abro.
The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
